Perrigo (Perrigo) Perrigo Company Public Limited Company (NYSE: PRGO) was founded in 1887 and is headquartered in Dublin, Ireland. It has 13,300 full-time employees. It is a manufacturer of over-the-counter drugs. The company’s products include painkillers, cough and cold medicines. , Antacids, laxatives and feminine hygiene products are sold through local supermarkets, pharmacies, hypermarkets and chain stores.
Perrigo Company (PRGO):
Perrigo Company PLC develops, produces and sells over-the-counter drugs (OTC), prescription drugs (Rx), nutritional products and APIs through its subsidiaries.
The products provided by Perico (Perico) include:
- Over-the-counter medicines include : medicine for pain relief, cough, cold, allergy, gastrointestinal, silt treatment, animal health care, and medicines for feminine hygiene products, diabetes care and skin care, and provide manufacturing services;
- Nutritional products include : infant formula milk products, infant food, vitamins, minerals and dietary fiber and other nutritional supplements;
- Prescription drugs include : creams, ointments, lotions, gels, sprays, liquids and powders, as well as injections, oral solid dosage forms, and oral liquid preparations.
Perek’s products are provided to consumers through chain pharmacies, wholesalers, distributors, and hospitals. The sales areas cover the United States, the United Kingdom, Mexico, Israel, Australia, and in Canada, the mainland and Latin America.
Perrigo Company (PRGO) History:
- In 1887, L. Perrigo Company, the predecessor of Perrigo Company, was founded by Luther and Charles Perrigo in Allegan, Michigan;
- In 1991, Perrigo Company’s initial public offering (IPO) on Nasdaq;
- In 2005, Perrigo acquired Agis Industries Ltd. (TASE: AGIS, founded by Moshe Arkin in 1983), an Irish general medicine company, for US$850 million;
- On January 9, 2008, Perrigo acquired Galpharm Healthcare, Ltd., a British OTC drug supplier;
- On September 16, 2008, Perrigo acquired JB Laboratories;
- On October 6, 2008, Perrigo acquired Laboratorios Diba SA, thus entering the Mexican market;
- On November 13, 2008, Perek acquired Unico Holdings, an American manufacturer of women’s & children’s hygiene products;
- On March 1, 2010, Perrigo Company acquired Orion Laboratories Pty, Ltd., an OTC drug manufacturer in Australia and New Zealand;
- On March 23, 2010, Perek acquired PBM Holdings, Inc., which is engaged in the production of OTC drugs, infant formula and baby food in the United States, Canada, China, Mexico and other places;
- On January 20, 2011, Perrigo Company acquired Paddock Laboratories Inc.;
- In September 2012, Perek acquired Sergeant’s Pet Care Products, Inc., an OTC animal medicine company, to enter the field of animal health;
- On February 11, 2013, Perrigo Company acquired Rosemont Pharmaceuticals Ltd., a professional and general prescription drug company focused on the production and sales of oral liquid preparations;
- On July 29, 2013, Perek acquired Elan Élan, a major pharmaceutical company headquartered in Dublin;
- In November 2014, Perrigo Company acquired Omega Pharma, a Belgian health product company for USD 4.5 billion, and the transaction was completed in March 2015;
- In April 2015, Perrik received a US$29 billion acquisition offer from Mylan , one of the world’s largest generic drug companies . CEO Joseph Papa rejected the terms of the acquisition. The following month, Joseph Papa left Perrigo Company and faced many difficulties. the Where Leah international drugs do CEO;
- On June 14, 2016, Perrigo Company confirmed that it would be acquired by a British company for US$20 billion, and its stock price rose 9%+;
- On August 8, 2018, Perrigo stated that the board of directors will consider a tax-free spin-off, sale or merger and acquisition transaction for the department, and plans to complete the relevant transaction in the second half of 2019; it believes that the separation of the department will create value for shareholders and allow the company to change. Focus on expanding consumer business. Perrigo lowered its full-year profit target on Thursday, and its shares fell 8.9%.